



ASX Announcement and Media Release

Thursday, April 14, 2011

SciGen Ltd

APPOINTMENT OF CHAIRMAN

The Board of Directors of SciGen Limited (ASX: SIE) (the “**SciGen**”) announce change in the Board.

APPOINTMENT OF CHAIRMAN

Following the resignation of Mr. Ryszard Krauze as Chairman on 22 March 2011, SciGen is pleased to announce the appointment of Mr. Sławomir Ziegert as the Chairman of the company. Mr. Sławomir Ziegert is also the CEO of the company.

Mr. Ziegert, is a doctor, graduate of the Medical University in Gdańsk. He is the President of the Management Board and CEO of Bioton SA. He has been connected with the pharmaceutical industry for over sixteen years, working in Poland and abroad for such concerns as Eli Lilly, Egis Group (a part of Servier group) and Ipsen. He has got business experience covering different sectors of the pharmaceutical industry, including biotechnology, in particular business development within the scope of endocrinology and treatment of diabetes.

From 1993 to 2004 Mr. Sławomir Ziegert worked in the Polish branch of Eli Lilly, one of the world's leading pharmaceutical concerns and manufacturers of recombinant human insulin and insulin analogues, where he was responsible for the development of diabetes business, relations with the diabetes environment and governmental affairs. In 1998-2000 he was also Eli Lilly's Country Manager in Slovakia, supervising, among others, the development of sale of insulins and antibiotics. He served also as the CEO of Egis Pharmaceuticals (a part of Servier group) with responsibility for the Baltic States area and as CEO of Ipsen Poland.

About SciGen

SciGen Ltd is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen

focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in Australia, South Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China and a contract manufacturer in Poland, Bioton S.A.

For further information: Company - Investor Relations	Company
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: gdunlop@scigen.com.au	Slawomir Ziegert CEO SciGen Ltd +65 6779 6638